Long Term Safety and Efficacy of Pasireotide s.c. in Patients With Cushing's Disease
Public ClinicalTrials.gov record NCT02310269. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Non-interventional Study for the Generation of Long Term Safety and Efficacy Data of Pasireotide s.c. in Patients With Cushing's Disease (Post-Authorization Safety Study)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a non-interventional, multinational, multi-center post-marketing study, to further document the safety and efficacy of pasireotide s.c. administered in routine clinical practice in patients with Cushing's disease. Patients with Cushing's disease and treated with pasireotide s.c. alone and in combination with other therapies will be monitored. For this study, each enrolled patient will be followed up for 3 years after enrollment. Patients who permanently discontinue pasireotide s.c. prior to completing the 3-year observation period will be followed up for 3 months after the last dose of pasireotide s.c.
Study identification
- NCT ID
- NCT02310269
- Recruitment status
- Completed
- Study type
- Observational
- Phase
- Not listed
- Enrollment
- 152 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 27, 2013
- Primary completion
- Jul 9, 2023
- Completion
- Jul 9, 2023
- Last update posted
- Oct 14, 2024
2013 – 2023
United States locations
- U.S. sites
- 7
- U.S. states
- 7
- U.S. cities
- 7
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| St Josephs Hospital and Medical Center | Phoenix | Arizona | 85013 | — |
| University of Southern California CSOM230B2410 - SC | Los Angeles | California | 90033 | — |
| Massachusetts General Hospital SC - SOM230B2410 | Boston | Massachusetts | 02114 | — |
| Ohio State University SC - SOM230B2410 | Columbus | Ohio | 43210 | — |
| Endocrinology Services | Bend | Oregon | 97702 | — |
| Allegheny Endocrinology Associates | Pittsburgh | Pennsylvania | 15212 | — |
| Swedish Medical Center Dept.ofSeattle Neuroscience(2) | Seattle | Washington | 98122-4379 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 47 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02310269, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 14, 2024 · Synced Sep 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02310269 live on ClinicalTrials.gov.